Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma

(Cancer Cell 38, 500–515.e1–e3; October 12, 2020) In this article, we report that T cell-induced interferon-γ correlates to response to immune checkpoint blockade therapy in melanoma patients. We would like to provide two additional supplemental tables. Table S1 details unidentifiable demographic information of patients to facilitate the re-analysis of the data based on specific patient characteristics or subgroups of melanomas. Table S2 contains the 549 interferon-γ-induced genes in melanoma cell lines that are mentioned in the article. These supplemental tables are now cited in the online version of the article and are provided with this article online. Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in MelanomaGrasso et al.Cancer CellSeptember 10, 2020In BriefAnalyzing the transcriptome of biopsies of patients during immune checkpoint blockade therapy, Grasso et al. show that the increase of T cell infiltration and the downstream IFN-γ signaling drive clinical responses. Full-Text PDF